• Menu
  • Skip to right header navigation
  • Skip to main content

Before Header

Call us today at (720) 328-8501Go to Prospect Life Sciences LinkedIn page Client Login

Prospect Life Sciences

Prepare to Prosper

  • WHAT WE DO
    • Devices We Make
    • NPI Services
    • Production Services
    • Fulfillment Services
    • À La Carte Services
  • HOW WE DO IT
    • Contract Manufacturing Solutions
    • Supply Chain Management
    • Quality Systems Management
    • Project Management
    • Onsite Features
    • Partnerships & Grant Support
  • THE PLS DIFFERENCE
    • Core Values
    • Our Team
    • Why People Like Us
  • NEWS & EVENTS
  • NOW HIRING
  • CONTACT US
  • What We Do
    • Devices We Make
    • NPI Services
    • Production Services
  • How We Do It
    • Supply Chain Management
    • Quality Systems Management
    • Project Management
    • Onsite Features
    • Partnerships and Grant Support
  • The PLS Difference
  • News & Events
  • Contact Us

news

Visit PLS at MD&M West

January 3, 2023 By //  by PLS

Join us Feb 7-9, 2023 for MD&M West in Anaheim, CA. We’ll be in Booth 1347 and look forward to seeing you.

Filed Under: news

Spinal Stabilization Technologies in LOPAIN2 Trial

December 10, 2022 By //  by PLS

Congratulations to Spinal Stabilization Technologies on beginning their LOPAIN2 clinical trial, measuring the efficacy of the PerQdisc Nucleus Replacement Device (NRD).

Filed Under: news

Allotrope Medical, Inc. Earns FDA Safer Technologies Program (STeP) Designation

November 9, 2022 By //  by PLS

Congratulations to Allotrope Medical Inc. on receiving a Safer Technologies Program (STeP) designation for their StemSite surgical device. Inclusion in STeP indicates that this medical device is expected to significantly improve the safety of currently available treatments. Read the full story to learn more.

Filed Under: news

PLS Attends MPO Summit 2022

October 24, 2022 By //  by PLS

We had a great time at the MPO Summit in Austin, TX. It is always a treat to spend quality time networking, learning, and forging new relationships with med device entrepreneurs and innovators.

Filed Under: news

PLS Attends Rocky Mountain Life Sciences Investor and Partnering Conference

September 15, 2022 By //  by PLS

What’s better than spending a couple of days in Vail, CO? Being there as part of Colorado BioScience Association’s partnering conference. The caliber of talent was impressive and we were happy to be able to share our medical device manufacturing expertise and capabilities with some of the industry’s emerging entrepreneurs.

Filed Under: news

LUCI Announces Partnership with NREL

March 31, 2022 By //  by PLS

In partnership with the U.S. Department of Energy’s National Renewal Energy Laboratory (NREL), LUCI announced they will working to create better alternatives to airport walkways.

Filed Under: news

Visit PLS at MD&M West, April 12-14, 2022

January 24, 2022 By //  by PLS

Prospect is excited to be exhibiting at MD&M West again this year. Come see us in Booth #3278.

Filed Under: news

Paragon28 Receives FDA Approval for Patient Specific Titanium Talus Spacer

December 14, 2021 By //  by PLS

Congratulations to Paragon28 on having their Patient Specific Titanium Talus Spacer approved by the FDA. Read the full press release for details.

Filed Under: news

Visit us at CBSA’s Innovation Forward

September 23, 2021 By //  by PLS

We are excited to be both attending and exhibiting at Colorado BioScience Association’s Innovation Forward: Forum + Awards Celebration Tuesday October 12, 2021. Come see us in Booth 16!

Filed Under: news

SST Earns CE Mark and FDA “Breakthrough Designation”

July 13, 2021 By //  by PLS

Congratulations to Spinal Stabilization Technologies, LLC (SST) on earning the CE mark and the FDA’s “breakthrough designation” for its PerQdisc™ Nucleus Replacement System. Read the full press release here.

Filed Under: news

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to Next Page »

Copyright © 2023 Prospect Life Sciences · All rights reserved. View our Privacy Policy.